ImmunoScape’s Deep Immunomics platform utilizes proprietary combinatorial barcoding technologies allowing discovery of rare, therapeutically relevant T cells and their T cell receptor (TCR). Our platform allows large scale T cell mining of patient samples while retaining extraordinarily high sensitivity, regularly detecting antigen-specific CD8 T cells at frequencies as low as 0.001%.
Deep Immunomics Platform Technology
1. PBMC or TIL samples from patients with disease of interest
- ImmunoScape’s Deep Immunomics platform is agnostic to sample type enabling mining of T cells from peripheral blood and tumor-infiltrating lymphocytes
- Our library of highly prevalent HLA alleles enables identification of antigen-specific T cells in ~85% of patients across North America, Europe, and Eastern Asia
2. TargetScape®
- ImmunoScape’s proprietary target screening platform mines hundreds to thousands of samples at the millions of cells scale
- We routinely screen samples using peptide-MHC multimers representing hundreds of candidate TCR targets
- We identify samples with T cells of therapeutic interest and use their phenotype to guide hit selection
3. TCR Antigen Profiling (TAP)
- We focus single cell sequencing efforts on tumor antigen-specific T cells identified and prioritized using TargetScape®
- TCR sequence, phenotype, gene expression, and clonality data are extracted from prioritized T cells at the thousands of cells scale
4. TCR Assessment
- We evaluate and prioritize novel tumor antigen-specific TCRs identified using TAP
- TCRs are advanced into further development based on in vitro and in vivo models of efficacy, safety, and specificity